Our scientific philosophy is rooted in leveraging deep biological understanding to build Scailyte’s pipeline of clinically impactful diagnostics and CDx. We achieve this by integrating multimodal data – with unparalleled expertise in high-resolution single-cell analysis – through our unbiased and explainable AI. This allows us to discover, validate, and translate the robust predictive signatures that form the core of our precision medicine products.
High clinical trial failure rates and limited drug efficacy often stem from the immense complexity underlying disease and drug response. Today, technologies like single-cell and multi-omics offer an unprecedented window into this complexity, generating a ‘tsunami’ of high-resolution data. This data holds the promise of revolutionizing how novel targets are discovered, patients are stratified, and mechanisms are understood – forming the basis for next-generation precision medicine solutions.
For pioneers in precision medicine, including drug and diagnostics developers, harnessing this data effectively means:
Extracting truly meaningful, actionable insights from this vast landscape requires a new generation of analytical power – a challenge Scailyte addresses through its innovative AI platform and focused pipeline development.
At Scailyte, we believe an integrative approach is essential for true progress. We harness deep, multimodal biological data, leveraging the unparalleled resolution of single-cell technologies alongside other omics, and analyze it with our sophisticated, unbiased, and explainable AI. Beyond generating insights, our core driving principle is clinical translation: transforming our discoveries into Scailyte’s own pipeline of robust, clinically validated diagnostic and CDx products that address critical unmet patient needs.
Conventional single-cell analysis often relies on clustering and annotating known cell types, an approach that requires prior knowledge and can dilute or even miss crucial signals by losing single-cell resolution. Scailyte breaks this mold. Our ScaiVision platform utilizes a supervised representation learning method. This unbiased, cluster-free approach identifies complex molecular patterns associated directly with clinical outcomes (like treatment response) without needing pre-defined cell types. This allows us to discover vital biological signals from previously unknown or rare cell populations – insights often obscured by standard methods, providing a deeper, more accurate picture of disease and treatment effects.
This unique capability is crucial for Scailyte to discover the highly specific and sensitive predictive biomarkers and diagnostic signatures that form our pipeline, giving us a distinct advantage in developing solutions where conventional methods fall short.
Scailyte’s AI extracts cellular and molecular insights through representation learning
Dive into our new video series and discover how Scailyte transforms complex single-cell and multi-omics data from a research tool into actionable clinical insights. In this series, we explore the unique capabilities of our ScaiVision AI platform and its approach to delivering robust, translatable biomarkers.
In Episode 1 of our ScaiVision video series, our Director of Data Science, Sarah Carl, indrpduces the background on single-cell technologies and overview of ScaiVision, with a focus on the preprocessing steps to ensure high-quality data and give the best chance for successful discoveries.
Understanding complex biology is fundamental to developing Scailyte’s pipeline of transformative diagnostic and CDx solutions. ScaiVision is engineered to thrive on this complexity, seamlessly integrating a wide array of data types to build the comprehensive biological picture necessary for our discoveries. Our platform’s flexibility allows us to leverage the most informative combination of data modalities to fuel our internal programs, with deep expertise across:
By integrating these diverse data streams, ScaiVision uncovers complex interactions and builds more robust biological models than possible with any single modality. This provides the truly holistic understanding critical for Scailyte to develop highly effective predictive biomarkers and innovative diagnostic/CDx solutions for our pipeline.
Furthermore, this deep multimodal understanding enables ScaiVision to be uniquely adept at training on a wide range of clinically-relevant endpoints. This allows us to transform complex biological profiles into the precise, actionable predictions that form the core of our diagnostic and CDx pipeline products. We develop models for outcomes such as:Diagnosis: Classifying disease states or subtypes (e.g., differential diagnosis and prognosis).
Case Highlight: ScaiVision vs. Standard Analysis. In a CAR T scRNAseq study, conventional methods missed key signals in CD4/CD8 T cells for predicting neurotoxicity. ScaiVision’s ability to maintain single-cell resolution identified the full signature, boosting predictive accuracy from 58% to 100%. See how we uncover insights others miss.
White Paper: Tackling complex single-cell data for clinical prediction demands accuracy and reliability. In a rigorous benchmarking study, ScaiVision outperformed competitors, demonstrating superior predictive power (0.96 AUC) and robustness across diverse cohorts. Discover why our AI delivers.
Item #2 Description
Item #3 Description
Item #4 Description
Item #5 Description
Item #6 Description
